Other Transactions are a unique type of legal funding instrument. Through unconventional processes, Other Transactions allow us to address rapidly evolving research areas.
Since launching in 2017, NIH’s Next Generation Researchers Initiative (NGRI) is continuing to address longstanding challenges faced by researchers trying to embark upon and sustain independent research careers as well as to promote the stability and diversity of the biomedical research workforce. Today, we are sharing data on our progress towards increased support for ESIs and other targeted groups.
We appreciate the many thoughtful comments posted to the blog about working together to improve NIH funding support for early- and mid-career investigators to stabilize the biomedical workforce and research enterprise using a measure called the Grant Support Index (GSI). Some clear themes have emerged, including: ….
NIH realizes that, as stewards of the American investment in biomedical sciences, we must do all we can to protect the future of the biomedical research enterprise, taking additional measures regardless of our budget situation. In the opening pages of this blog, we noted that our increasingly hypercompetitive system is threatening the future of biomedical research and of the hundreds of thousands of scientists who we look to for discovering tomorrow’s cures. This is a strange irony, given that the last 25-50 years have been times of extraordinary discovery and progress in basic, translational, and applied science. Death rates from cardiovascular disease have plummeted, and death rates from cancer are falling steadily. Scientists have a much deeper understanding of human biology to the point where this knowledge can drive the design of drugs and biologics. Big data and high-throughput technologies now enable rapid development and testing of hypotheses that previously would have taken years. The successes are myriad. But so are the problems, problems so real that some have gone so far as to write, “It is time to confront the dangers at hand and rethink some fundamental features of the US biomedical research system.” ….